Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-interleukin-5 therapy in severe asthma.

European respiratory review : an official journal of the European Respiratory Society - 1 Sept 2013

Garcia Gilles, Taillé Camille, Laveneziana Pierantonio, Bourdin Arnaud, Chanez Pascal, Humbert Marc

Abstract excerpt

Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms, exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal exacerbations. This as yet significant minority of individuals present with severe asthma and have persisting daily symptoms, and exacerbations despite compliance with high doses of inhaled steroids and additional treatment. For more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Anti-Inflammatory Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma

Share to Disease Progression

Share to Interleukin-5

Share to Patient Selection

Share to Severity of Illness Index

Source

Open in PubMed Open full text

Identifiers

PMID: 23997052
DOI: 10.1183/09059180.00004013
PMCID: PMC9487362

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-interleukin-5 therapy in severe asthma.PMID 23997052Read ↗

Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthmaSemantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

What goes up must come down: biomarkers and novel biologicals in severe asthma.Semantic proximity Read ↗

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read ↗

Reslizumab in the treatment of severe eosinophilic asthma: an update.Semantic proximity Read ↗

Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity Read ↗

Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic FrontiersSemantic proximity Read ↗

Targeted therapeutics for severe refractory asthma: monoclonal antibodies.Semantic proximity Read ↗

Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals.Semantic proximity Read ↗

IL-5 and IL-5 receptor in asthmaSemantic proximity Read ↗

Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for bothSemantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.